Anti-FA9/ F9/ F9 p22 monoclonal antibody

Anti-FA9/ F9/ F9 p22 antibody for FACS & in-vivo assay

Target products collectionGo to F9/F9 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T83369-Ab-1/ GM-Tg-hg-T83369-Ab-2Anti-Human F9 monoclonal antibodyHuman
GM-Tg-rg-T83369-Ab-1/ GM-Tg-rg-T83369-Ab-2Anti-Rat F9 monoclonal antibodyRat
GM-Tg-mg-T83369-Ab-1/ GM-Tg-mg-T83369-Ab-2Anti-Mouse F9 monoclonal antibodyMouse
GM-Tg-cynog-T83369-Ab-1/ GM-Tg-cynog-T83369-Ab-2Anti-Cynomolgus/ Rhesus macaque F9 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T83369-Ab-1/ GM-Tg-felg-T83369-Ab-2Anti-Feline F9 monoclonal antibodyFeline
GM-Tg-cang-T83369-Ab-1/ GM-Tg-cang-T83369-Ab-2Anti-Canine F9 monoclonal antibodyCanine
GM-Tg-bovg-T83369-Ab-1/ GM-Tg-bovg-T83369-Ab-2Anti-Bovine F9 monoclonal antibodyBovine
GM-Tg-equg-T83369-Ab-1/ GM-Tg-equg-T83369-Ab-2Anti-Equine F9 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T83369-Ab-1/ GM-Tg-hg-T83369-Ab-2; GM-Tg-rg-T83369-Ab-1/ GM-Tg-rg-T83369-Ab-2;
GM-Tg-mg-T83369-Ab-1/ GM-Tg-mg-T83369-Ab-2; GM-Tg-cynog-T83369-Ab-1/ GM-Tg-cynog-T83369-Ab-2;
GM-Tg-felg-T83369-Ab-1/ GM-Tg-felg-T83369-Ab-2; GM-Tg-cang-T83369-Ab-1/ GM-Tg-cang-T83369-Ab-2;
GM-Tg-bovg-T83369-Ab-1/ GM-Tg-bovg-T83369-Ab-2; GM-Tg-equg-T83369-Ab-1/ GM-Tg-equg-T83369-Ab-2
Products NameAnti-F9 monoclonal antibody
Formatmab
Target NameF9
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-F9 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-INN-726Pre-Made Albutrepenonacog Alfa Biosimilar, Fusion Protein targeting F9 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8
    BiosimilarGMP-Bios-INN-929Pre-Made Nonacog Gamma Biosimilar, Recombinant Protein targeting F9: Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8
    BiosimilarGMP-Bios-INN-792Pre-Made Dalcinonacog Alfa Biosimilar, Recombinant Protein targeting F9: Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8
    BiosimilarGMP-Bios-ab-177Pre-Made Emicizumab biosimilar, Bispecific mAb, Anti-F9;F10 Antibody: Anti-FIX/HEMB/P19/PTC/THPH8;FX/FXA therapeutic antibody
    BiosimilarGMP-Bios-INN-830Pre-Made Eftrenonacog Alfa Biosimilar, Fusion Protein targeting F9 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8
    Target AntigenProducts DevelopingMulti-species FA9/ F9/ F9 p22 VLP (virus-like particle) (Products Developing)
    ORF Viral VectorvGMAP000457Human F9 Adenovirus particle
    ORF Viral VectorpGMAD000413human F9 Adenovirus plasmid
    ORF Viral VectorpGMAP000457Human F9 Adenovirus plasmid
    ORF Viral VectorvGMAD000413human F9 Adenovirus particle
    ORF Viral VectorpGMLPm002073mouse F9 Lentivirus plasmid
    ORF Viral VectorvGMLPm002073mouse F9 Lentivirus particle


    Target information

    Target IDGM-T83369
    Target NameF9
    Gene ID2158,14071,24946,695578,404015,493973,100054449
    Gene Symbol and SynonymsCf-9,Cf9,F9,F9 p22,FIX,HEMB,P19,PTC,THPH8
    Uniprot AccessionP00740,P16296,P19540,Q6SA95
    Uniprot Entry NameFA9_HUMAN,FA9_RAT,FA9_FELCA,FA9_CANLF
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, INN Index
    DiseaseN/A
    Gene EnsemblENSG00000101981
    Target ClassificationN/A

    The target: F9, gene name: F9, also named as F9 p22, FIX, HEMB, P19, PTC, THPH8. This gene encodes vitamin K-dependent coagulation factor IX that circulates in the blood as an inactive zymogen. This factor is converted to an active form by factor XIa, which excises the activation peptide and thus generates a heavy chain and a light chain held together by one or more disulfide bonds. The role of this activated factor IX in the blood coagulation cascade is to activate factor X to its active form through interactions with Ca+2 ions, membrane phospholipids, and factor VIII. Alterations of this gene, including point mutations, insertions and deletions, cause factor IX deficiency, which is a recessive X-linked disorder, also called hemophilia B or Christmas disease. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing. [provided by RefSeq, Sep 2015].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.